Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Background/Aims Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge. Methods Using data f...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Format:	Artigo
Idioma:	Inglês
Publicat:	Korean Association for the Study of the Liver 2024-10-01
Col·lecció:	Clinical and Molecular Hepatology
Matèries:	hepatocellular carcinoma immunotherapy atezolizumab bevacizumab transcriptome
Accés en línia:	http://e-cmh.org/upload/pdf/cmh-2024-0333.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!